Literature DB >> 12649194

Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium.

Michael Danilenko1, Qing Wang, Xuening Wang, Joseph Levy, Yoav Sharoni, George P Studzinski.   

Abstract

Differentiation therapy of cancer remains an only partially attained goal. Agents currently under active investigation include derivatives of vitamin D, modeled on its physiological hormone form, 1alpha,25-dihydroxyvitamin D(3) (1,25D(3)), but the calcemic effects of these compounds preclude their use in the clinic. An approach that may obviate this problem is to combine 1,25D(3) or its derivatives with other agents that increase the antineoplastic effects of low, nontoxic concentrations of vitamin D compounds. We have recently used the plant-derived polyphenolic antioxidant, carnosic acid (CA), to demonstrate an increase in the differentiating action of 1,25D(3) on human leukemia cells under these conditions (M. Danilenko et al., JNCI, 93: 1224-1233, 2001). We now show that treatment of HL60-G cells with either CA or 1,25D(3) alone resulted in a decrease in the intracellular levels of reactive oxygen species. Furthermore, the combination of 10 micro M CA and a low concentration of 1,25D(3) (1 nM) produced an enhanced antioxidant effect, which correlated with the potentiation of monocytic differentiation. Other plant antioxidants tested (curcumin, silibinin, and the organoselenium antioxidant ebselen) also potentiated differentiation induced by 1,25D(3), although alone, they had only minor differentiating effects. Differentiation induced by CA/1,25D(3) combinations was associated with increased intracellular glutathione content, whereas buthionine sulfoxime decreased both differentiation and the cellular glutathione content. This combination also enhanced the activation of the Raf-mitogen-activated protein/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase mitogen-activated protein kinase module and increased the binding of the activator protein-1 (AP-1) transcription factor to its cognate DNA element in the promoter regions of vitamin D receptor gene, suggesting that the mechanism of potentiation is at least in part attributable to induction and activation of components of this mitogen-activated protein kinase pathway. Cell treatment with a high concentration of 1,25D(3) (100 nM) resulted in a substantial elevation of basal intracellular calcium concentration. In contrast, importantly for an eventual clinical application of these studies, the potentiating action of CA on differentiation induced by a low concentration of 1,25D(3) (1 nM) was not accompanied by an elevation of basal intracellular calcium concentration. These findings suggest that combinations of CA with derivatives of vitamin D should be evaluated for use in differentiation therapy of myeloid leukemias.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649194

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.

Authors:  Xuening Wang; Jonathan S Harrison; George P Studzinski
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-28       Impact factor: 4.292

2.  Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia.

Authors:  Hagar Sharabani; Eugene Izumchenko; Qing Wang; Rita Kreinin; Michael Steiner; Zeev Barvish; Michael Kafka; Yoav Sharoni; Joseph Levy; Milan Uskokovic; George P Studzinski; Michael Danilenko
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

3.  Change in the Ca2+ response to formyl peptide in HL-60 myeloblastic leukemia cells after the induction of their differentiation by MP-4 myelogenic peptide.

Authors:  E I Astashkin; N I Suvorov; A A Mikhailova; S V Grachev
Journal:  Dokl Biol Sci       Date:  2006 May-Jun

4.  The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells.

Authors:  Irene Bobilev; Victoria Novik; Itai Levi; Ofer Shpilberg; Joseph Levy; Yoav Sharoni; George P Studzinski; Michael Danilenko
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

5.  Trimetazidine decreases Ca2+ response to thapsigargin in differentiated and undifferentiated human HL-60 cells.

Authors:  E I Astashkin; M G Glezer; S V Grachev
Journal:  Dokl Biol Sci       Date:  2007 Jan-Feb

6.  Trimetazidine selectively inhibits SOC channels in plasma membranes of human HL-60 cells and does not affect the intracellular Ca2+ stores.

Authors:  E I Astashkin; M G Glezer; S V Grachev
Journal:  Dokl Biol Sci       Date:  2009 Jan-Feb

Review 7.  Vitamin D and differentiation in cancer.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

8.  Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination.

Authors:  Qunfeng Wu; Xuening Wang; Kien Pham; Aesis Luna; George P Studzinski; Chen Liu
Journal:  J Steroid Biochem Mol Biol       Date:  2019-11-05       Impact factor: 4.292

9.  Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia.

Authors:  Ayelet Shabtay; Hagar Sharabani; Zeev Barvish; Michael Kafka; Doron Amichay; Joseph Levy; Yoav Sharoni; Milan R Uskokovic; George P Studzinski; Michael Danilenko
Journal:  Oncology       Date:  2008-10-14       Impact factor: 2.935

10.  Carnosic acid biosynthesis elucidated by a synthetic biology platform.

Authors:  Codruta Ignea; Anastasia Athanasakoglou; Efstathia Ioannou; Panagiota Georgantea; Fotini A Trikka; Sofia Loupassaki; Vassilios Roussis; Antonios M Makris; Sotirios C Kampranis
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.